News & Events
PNOC0026 open for patient enrollment, August 30th 2021
The purpose of this study is to evaluate the efficacy and safety of DAY101 in pediatric patients aged 6 months to 25 years of age as monotherapy in pediatric patients with a recurrent or progressive LGG harboring a known activating BRAF alteration. The primary endpoint is ORR as defined by the RANO criteria, determined by an IRC.
Retreat Meeting of DIPG/DMG Center in Zurich July 6th 2021
Pre-clinical as well as clinical researchers and tem members joined in July 2021 for a retreat meeting at Campus Balgrist, Zurich. Current and upcoming trials and research projects as well as planned grants were presented and discussed. An update was also given on the FUS project by Dr. Beat Werner. It was very valuable to share the development so far and the achieved goals with the whole team. Especially after such a long period of distance keeping and video conferencing due to pandemic related restrictions.
Yuvaan Tiwari Postdoctoral Fellowship at University Children’s Hospital Zurich, starting July 1st
We are very honored and grateful for the generous donation we received from Satya and Parvati Tiwari to establish the “Yuvaan Tiwari Postdoctoral Fellowship” at the DIPG/DMG Research Center, led by Prof. Dr. Javad Nazarian. Dr. Evan Santos will start this position on July 1, 2021. This donation will enable to further advance research on these deadly tumors.
PNOC019 open for patient enrollment, April 14th 2021
This international, multi-center clinical trial is open for patients (6 months – 22 years) with recurrent or progressive High Grade Glioma (HGG). The study aims to evaluate the immunological local and systemic changes following neoadjuvant checkpoint inhibition, as well as the preliminary efficacy of neoadjuvant checkpoint inhibition followed by surgery and adjuvant combination checkpoint inhibition in children and young adults with progressive or recurrent HGG.
PNOC007 open for patient enrollment, December 17th 2020
The purpose of this study is to test the safety and first signs of efficacy of a H3.3K27M specific peptide vaccine (K27M/TT), in combination with a drug called poly-ICLC and Nivolumab in children and young adults (3-21 years) that have been newly diagnosed with a diffuse intrinsic pontine glioma (DIPG) or another type of glioma. Thus is a multi-center clinical trial with multiple sites in the USA and one at the University Children’s Hospital Zurich in Switzerland.
SNF Sinergia Grant at DMG Center Zurich, November 26th 2020
The Swiss National Fund approved the Sinergia proposal of Dr. Javad Nazarian as the lead PI and Prof.Dr. Mehmet Fatih Yanik (ETH) and Dr.Sebastian Waszak (Centre for Molecular Medicine Norway) as co-applicants. With 3.1 Mio CHF over 4 years the team aims to merge novel technologies for rapid identification and validation of therapies capable of extending the survival of children diagnosed with diffuse midline gliomas. The proposal includes a stepwise process that employs expertise of a multidisciplinary team to achieve a significant impact on patient treatment options.
We are very much looking forward to first results from this interdisciplinary research team!
Trans-Atlantic DIPG/DMG Tumor board, November 9th 2020
The first Trans-Atlantic Tumor Board took place on November 9th, 2020 from 5 PM – 6 PM CET / 8 AM- 9 AM PT. More than 20 experts in the care of children and young adults with Diffuse Midline Glioma from UCSF and Zurich Children’s Hospital were present. The combined discussion with experts around the world truly enhances the evaluation and recommendations for these patients. The combined tumor board will take place on a weekly basis.